CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2006--Idera Pharmaceuticals (AMEX: IDP - News) today announced that it has expanded its portfolio of drug candidates targeting Toll-like Receptors (TLRs) to include novel RNA compounds that activate immune responses through TLR7 and TLR8 and novel DNA compounds that act to inhibit activity of TLR9. These novel compounds are the result of entirely in-house application of Idera’s expertise in DNA and RNA chemistry. The new preclinical data were announced in three presentations made at the Annual Meeting of the American Association of Immunologists (AAI) in Boston, MA, May 13 and 14, 2006.
